Cytosorbents (CTSO) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Q1 2026 revenue was $8.9 million, a 2% increase year-over-year but down 7% on a constant currency basis.

International Direct Sales: Grew 13% year-over-year, while sales in Germany declined.

Gross Margin: 69%, down from 71% year-over-year, attributed to intentional production slowdowns to manage inventory.

Operating Expenses: Reduced to $9.2 million from $10.1 million a year ago, reflecting cost-cutting measures.

Operating Loss: Improved to $3 million, a 22% reduction from $3.9 million in the prior year.

Net Loss: Increased to $5.1 million ($0.08 per share) from $1.5 million ($0.02 per share) due to noncash foreign currency impacts.

Adjusted Net Loss: Improved to $3.4 million ($0.05 per share) from $3.7 million ($0.06 per share).

Cash Position: Approximately $6.4 million at the end of Q1, down from $7.8 million at year-end.

2Strategic Updates and Business Highlights

Product Development: CytoSorb is approved in the EU for various indications, while DrugSorb-ATR is still investigational. The company is focusing on expanding its clinical applications and improving physician utilization strategies.

Market Expansion: The international core CytoSorb business is growing, with over 300,000 devices used in more than 70 countries. The company is also exploring opportunities in the Middle East despite geopolitical challenges.

Operational Improvements: The company is refining its sales strategy in Germany and plans to selectively rebuild its sales force to enhance market coverage.

Clinical Evidence: New data from the STAR-T trial supports the safety and efficacy of DrugSorb-ATR in reducing bleeding during cardiac surgery.

3Forward Guidance and Outlook

Regulatory Pathway: The company is preparing for a new de novo submission for DrugSorb-ATR, expected to be filed in late 2026 or early 2027. They aim to achieve operating cash flow breakeven in the second half of 2026.

Growth Expectations: Management remains optimistic about stabilizing and growing the German market, while international markets are showing promising growth.

4Bad News, Challenges, or Points of Concern

Geopolitical Risks: Delays in distributor orders in the Middle East due to the U.S.-Iran conflict impacted expected revenue by approximately $0.5 million.

Sales Decline in Germany: While there are signs of improvement, sales in Germany remain a concern, and the company is in the process of restructuring its sales force.

Increased Net Loss: The significant increase in net loss is concerning, primarily driven by noncash foreign currency impacts.

5Notable Q&A Insights

Regulatory Clarifications: The FDA has requested additional mechanistic data for DrugSorb-ATR, which will not require a clinical trial but will involve non-clinical studies. The specifics of these studies are still being finalized.

Expansion Plans: The company is optimistic about the potential for expanding DrugSorb-ATR's label to include direct oral anticoagulants (DOACs), with plans to submit a pre-submission request to the FDA shortly.

Middle East Market: Management expressed confidence in recovering delayed orders once geopolitical stability returns, highlighting ongoing interest from physicians in the region. Overall, Cytosorbents is navigating a challenging environment but is making strides in operational efficiency and clinical validation, with a focus on future growth opportunities.